| 5.67 -0.96 (-14.48%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.77  |
1-year : | 13.44 |
| Resists | First : | 9.22 |
Second : | 11.51 |
| Pivot price | 6.58 |
|||
| Supports | First : | 5.53 |
Second : | 4.6 |
| MAs | MA(5) : | 6.44 |
MA(20) : | 6.63 |
| MA(100) : | 6.43 |
MA(250) : | 13.12 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 39.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 80.09 | Low : | 2.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPRC ] has closed below the lower bollinger band by 39.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SPRC ] is to continue within current trading range. It is unclear right now based on current values. 78.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.85 - 5.88 | 5.88 - 5.91 |
| Low: | 5.45 - 5.49 | 5.49 - 5.52 |
| Close: | 5.6 - 5.66 | 5.66 - 5.72 |
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Tue, 01 Sep 2026
SciSparc Ltd. SEC Filing (Sep 1, 2026) - stocktitan.net
Mon, 31 Aug 2026
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - markets.businessinsider.com
Mon, 31 Aug 2026
26 children have joined SciSparc’s two-compound autism treatment trial - stocktitan.net
Wed, 26 Aug 2026
SciSparc (NASDAQ: SPRC) taps AI professor for new AI and cybersecurity board - stocktitan.net
Tue, 18 Aug 2026
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - stocktitan.net
Tue, 18 Aug 2026
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | 98.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.6 |
| Profit Margin | 0 % |
| Operating Margin | -849 % |
| Return on Assets (ttm) | -60.7 % |
| Return on Equity (ttm) | -178.4 % |
| Qtrly Rev. Growth | -34.5 % |
| Gross Profit (p.s.) | 1.1 |
| Sales Per Share | 1.49 |
| EBITDA (p.s.) | -14.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 3.79 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|